Abstract: The present invention relates to stable active compound complexes of salts of o-acetylsalicylic acid with basic amino acids and glycine, to a process for their preparation and to their use as medicaments.

Abstract: The present invention relates to a fixed combination comprising a salt of o-acetylsalicylic acid with a basic amino acid as component A and an HMG-CoA reductase inhibitor as component B, a medicament comprising this combination and a process for its production.

Abstract: The present invention relates to stable active compound complexes of salts of o-acetylsalicylic acid with basic amino acids and glycine, to a process for their preparation and to their use as medicaments.

Abstract: The present invention relates to stable salts of O-acetylsalicylic acid with basic amino acids, a process for their preparation and their use as medicaments.

Abstract: The present invention relates to improved compositions comprising stable salts of O-acetylsalicylic acid with basic amino acids, to pharmaceuticals comprising them and to their use for preparing pharmaceuticals.

Abstract: The present invention relates to stable salts of O-acetylsalicylic acid with basic amino acids, a process for their preparation and their use as medicaments.

Abstract: The present invention relates to stable salts of O-acetylsalicylic acid with basic amino acids, a process for their preparation and their use as medicaments.

Abstract: The present invention relates to stable salts of O-acetylsalicylic acid with basic amino acids, a process for their preparation and their use as medicaments.

Abstract: The present invention relates to a one-pot process for the preparation of 7-heterocyclyl-substituted 3-quinolonecarboxylic acid derivatives. They possess a strong anti-microbial effect. They include active compounds such as, for example, ofloxacin, ciprofloxacin or enrofloxacin.

Abstract: The invention relates to pharmaceutical preparations, containing a specific crystal modification (subsequently called "modification II") of isopropyl-(2-methoxyethyl) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate (nimodipine) and to a process for its preparation.

Abstract: The present invention relates to the use of 3-formyl-1,4-dihydropyridine derivatives as medicaments for the control of cardiovascular diseases, in particular of pathologically changed blood pressure and of cardiac insufficiency, new compounds and a process for their preparation.

Abstract: Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is H, CN, NO.sub.2 or --COOR.sup.7,R.sup.7 is H, alkyl or various other radicals,R.sup.2 and R.sup.4 each independently is alkyl or other radicals,R.sup.3 is H or optionally substituted alkyl, andR.sup.5 completes a keto or ester group,and physiologically acceptable salts thereof.

Abstract: Circulation-active fluoromethoxyphenyldihydropyridines of the formula ##STR1## in which X stands for hydrogen or fluorine andR stands for straight-chain, branched or cyclic alkyl or alkenyl having 2 to 12 carbon atoms which can be interrupted by 1 to 2 oxygen and/or sulphur atoms in the chain, and which can be monosubstituted or polysubstituted(a) by hydroxyl, aryl having 6 to 12 carbon atoms, aryloxy having 6 to 12 carbon atoms, where the aryl radical is again substituted by alkyl having up to 4 carbon atoms, alkoxy having up to 4 carbon atoms or halogen, the substituents being identical or different, or(b) by carboxyl, alkoxycarbonyl having up to 6 carbon atoms, pyridyl, piperidyl, pyrimidyl, acyloxy having up to 7 carbon atoms, sulphamoyl, carbamoyl, halogen or cyano, the substituents being identical or different, or(c) by an amino group, where the amino group can carry one or two identical or different substituents from the group consisting of alkyl having up to 6 carbon atoms, benzyl, phenyl or acyl havi

Abstract: Circulation active nitrodihydropyridines of the formula ##STR1## in which R represents aryl which has 6 to 12 carbon atoms and can be substituted up to 4 times, identically or differently, by halogen, nitro, cyano, alkyl, alkoxy, alkylthio, in each case having up to 6 carbon atoms, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio, difluoromethylenedioxy, trifluoroethylenedioxy or tetrafluoroethylenedioxy or by benzyl, benzyloxy or benzylthio, each of which is optionally substituted by halogen, nitro, cyano, trifuoromethyl, alkyl having up to 4 carbon atoms or alkoxy having up to 4 carbon atoms, or represents a heterocycle which is optionally substituted by halogen, phenyl or alkyl having up to 4 carbon atoms and is from the group consisting of pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidyl, pyridazinyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl, andn represents a number from 1 to 12,and physiologically acceptable salts thereof.

Abstract: A composition effective for treating circulation disorders comprises a mixture of ##STR1## wherein the variables can have varied meetings. I are inotropic and II are vasodilating but, whereas the ingredients in the combination would be expected to be antagonistic, they are reinforcing.

Abstract: Cardioactive novel dihydropyridine ethers of the formula ##STR1## in which R.sup.1 -stands for cyano, nitro or for a -COOR.sup.5 group,whereinR.sup.5 -denotes straight-chain, branched or cyclic alkyl having up to 6 carbon atoms, which can be interrupted by an oxygen in the chain and which can be monosubstituted or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxyl, phenyl, phenoxy or by a group of the formula ##STR2## R.sup.2 -stands for aryl having 6 to 12 carbon atoms, which can be monosubstituted, disubstituted or trisubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, alkyl having up to 4 carbon atoms or alkoxy having up to 4 carbon atoms,R.sup.3 -stands for aryl having 6 to 12 carbon atoms, or stands for straight-chain, branched or cyclic alkyl having up to 6 carbon atoms andR.sup.

Abstract: Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is H, CN, NO.sub.2 or --COOR.sup.7,R.sup.7 is H, alkyl or various other radicals,R.sup.2 and R.sup.4 each independently is alkyl or other radicals,R.sup.3 is H or optionally substituted alkyl,R.sup.5 completes a keto or ester group, andR.sup.6 is a direct bond or --CF.sub.2 -- or --CHF--,and physiologically acceptable salts thereof.

Abstract: For the control of coronary diseases and thromboses there are provided the novel compounds ##STR1## in which R.sup.1 is an optionally substituted phenyl or heterocyclic radical,R.sup.2 is a cyano, keto, carboxy, ester or amide group, andX is from 0 to 6,and physiologically acceptable salts thereof.

Abstract: For the treatment of circulation disorders, the novel 5-nitro-1,4-dihydropyridines of the formula ##STR1## in which R represents C.sub.6 -C.sub.14 -aryl which can be mono- to pentasubstituted by identical or different substituents from the series comprising halogen, nitro, cyano, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio and benzyl, benzyloxy or benzylthio optionally substituted by nitro, cyano, trifluoromethyl, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy, orrepresents a heterocycle from the series pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl optionally mono- to tetrasubstituted by halogen, phenyl or C.sub.1 -C.sub.4 -alkyl orrepresents straight-chain, branched or cyclic alkyl with up to 14 carbon atoms,and their physiologically acceptable salts.

Abstract: Novel circulation active dihydropyridines of the formula ##STR1## in which X is CO, SO.sub.2 or CONH,R.sup.4 is H, OH, alkyl, halogen, acyloxy, alkoxyalkoxy, aralkyloxy, or together with R.sup.5 forms a heterocyclic ring, andthe other radicals are conventional in the dihydropyridine art,and pharmaceutically acceptable salts thereof.